Mapping the T cell response to COVID-19 by Li, Junwei et al.
RESEARCH HIGHLIGHT OPEN
Mapping the T cell response to COVID-19
Junwei Li1, Junhua Wang1, Angray S. Kang 2 and Pradeep Kumar Sacitharan3,4
Signal Transduction and Targeted Therapy           (2020) 5:112 ; https://doi.org/10.1038/s41392-020-00228-1
A recent article by Grifoni et al. elegantly demonstrated the
ability to measure and understand the human CD4+ and CD8+
T cell responses to SARS-CoV-2 infection.1 These findings
highlighted below gave new insights into the immunopatho-
genesis of COVID-19, the crossreactivity of the SARS-CoV-2
infections, the potential targets of T cells, and for vaccine
design.
COVID-19 is a deadly global pandemic that spread across the
world in a short time frame.2,3 Currently it is unknown how T cells,
which comprise a major part of the adaptive immune response,
react to the virus.4 Understanding the T cell response to the SARS-
CoV-2 (virus which causes COVID-19) can aid vaccine development
and increase our understanding on immunopathogenesis of the
disease. Furthermore, accessing T cells responses in affected and
non-affected patients can inform us on protective immunity to the
virus. The authors set out to address these shortcomings by
examining the T cells responses in patients who had recovered
from SARS-CoV-2 infection with COVID-19 disease and unexposed
individuals.1
The research group previously developed the megapool (MP)
approach to allow simultaneous testing of large numbers
epitopes, in particular when sample size may be limiting.5 The
group then analyzed the bloods from 20 adult patients who had
recovered from COVID-19 disease and local healthy control
donors. Using flow cytometry to broadly assess the immunolo-
gical cellular profile of recovered COVID-19 patients the authors
showed the frequency of CD3+ cells was slightly increased in
recovered COVID-19 patients relative to non-exposed controls,
while no significant differences overall were observed in the
frequencies of CD4+ or CD8+ T cells between the two groups.
This elegant approach showed recovered COVID-19 patients
consistently generated a substantial CD4+ T cell response
against SARS-CoV-2. The SARS-CoV-2−specific CD4+ T cells were
functional, as the cells produced IL-2 in response to non-spike
and spike MPs. Polarization of the cells appeared to be a classical
TH1 type, as substantial IFNγ was produced while little or no IL-4,
Il-5, IL-13, or IL-17α was expressed. Most importantly the studies
showed on average ~50% of the detected response was directed
against the spike protein, and ~50% was directed against the MP
representing the remainder of the SARS-CoV-2 orfeome. This is
of significance, since the SARS-CoV-2 spike protein is a key
component of the vast majority of candidate COVID-19 vaccines
currently under development. The authors also detected IFNγ+
SARS-CoV-2−specific CD8+ T cells in the majority of COVID-19
cases. The majority of IFNγ+ cells co-expressed granzyme B and
a substantial fraction of the IFNγ+ cells expressed TNF, but not
IL-10. These data demonstrated the majority of recovered
COVID-19 patients generated a CD8+ T cell response against
SARS-CoV-2.
The authors next asked the question of whether stronger
SARS-CoV-2-specific CD4+ T cell responses were associated with
higher antibody titers in COVID-19 cases. This is an important
question because most protective antibody responses are
dependent on CD4+ T cell help. The authors with keen insight
examined spike-specific CD4+ T cells because the spike
component of the virus is the primary target of SARS neutralizing
antibodies. The data showed spike-specific CD4+ T cell responses
correlated well with the magnitude of the anti-spike receptor
binding domain (RBD) IgG titers. This part of the study also
showed CD4+ and CD8+ T cell responses to SARS-CoV-2 were
generally well correlated.
For the final set of experiments in the article, the authors
synthesized sets of overlapping peptides spanning the entire
open reading frame of SARS-CoV-2 and pooled them separately
so that each pool would represent one polypeptide. By doing
this the authors hoped to understand which antigens are
targeted by CD4+ and CD8+ T cells, whether the corresponding
antigens are the same or different, and how do they compare to
the antigens currently considered for COVID-19 vaccine devel-
opment. SARS-CoV-2-specific CD4+ T cell targets included SARS-
CoV-2 ORFs spike, M, and N which accounted for accounted for
27, 21, and 11% of the total CD4+ T cell response, respectively.
The data also indicated a somewhat different pattern of
immunodominance for SARS-CoV-2 CD8+ T cell reactivity with
spike protein accounting for ~26% of the reactivity, and N
accounting for ~12%. These results concluded that CD8+ T cell
crossreactivity exists but is less widespread than CD4+ T cell
crossreactivity.
In summary, Grifoni et al. provided critical knowledge that
showed circulating SARS-CoV-2-specific CD8+ and CD4+ T cells
were identified in ~70 and 100% of COVID-19 patients,
respectively. CD4+ T cell responses to spike, the main target of
most vaccine efforts, were robust and correlated with the
magnitude of the anti-SARS-CoV-2 IgG and IgA titers. The authors
also showed total CD4+ response was directed at the M, spike,
and N proteins each accounted for 11–27% with additional
responses commonly targeting nsp3, nsp4, ORF3a, and ORF8,
among others. For CD8+ T cells, spike and M were recognized,
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with at least eight SARS-CoV-2 ORFs targeted. Importantly, the
authors detected SARS-CoV-2−reactive CD4+ T cells in ~40–60%
of unexposed individuals, suggesting cross-reactive T cell
recognition between circulating ‘common cold’ coronaviruses
and SARS-CoV-2. However, further studies are required on
samples from acute patients and patients with complicated
disease courses which will tell us the T cell responses for the
whole duration of the disease. In addition, the common cold
history and matched blood samples were not fully detailed for
each patient. These data could provide us with more conclusions
regarding the abundance of crossreactive coronavirus T cells
before exposure to SARS-CoV-2. Moreover, further studies on the
longevity of the SARS-CoV-2 immunological memory have to be
conducted on samples from recovered patients. Nonetheless,
Grifoni et al. provided the first key insights on how T cells
respond to this deadly virus (Fig. 1).
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Fig. 1 Measuring the T cell response to SARS-CoV-2 is critical for understanding COVID-19. Epitope pools detected CD4+ and CD8+ T cells in
100 and 70% of recovering COVID patients. T cell responses are focused not only on spike but also on M, N, and other ORFs. In addition, T cell
reactivity to SARS-CoV-2 epitopes are also present in non-exposed individuals
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